Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This Phase I/II safety study is designed to investigate the safety and efficacy of
ranibizumab (Lucentis) in the treatment of polypoidal choroidal vasculopathy (PCV), a
potentially blinding eye disease that involves the growth of tiny, abnormal blood vessels
under the retina. These abnormal blood vessels can bleed or leak fluid, causing disruption of
normal retinal function and vision loss. Ranibizumab is a drug that is FDA-approved for the
treatment of wet age-related macular degeneration (AMD) and is injected directly into the
eye. Given the efficacy of ranibizumab in the treatment of wet AMD, and the postulated
similarity between the disease mechanisms involved in both wet AMD and PCV, we believe
ranibizumab will have a beneficial effect on visual function in patients with PCV.